Clinical improvement of hyperglycemia after use of octreotide lar in a patient with acromegaly who presented with nonketotic hyperosmolar state

Umit Cavdar; Nilufer Ozdemir; Bercem Aycicek; Halit Diri

doi:10.1530/endoabs.56.EP122

EP122

Prev Next

Section Contents Cite

Endocrine Abstracts (2018) 56 EP122 | DOI: 10.1530/endoabs.56.EP122

ECE2018 ePoster Presentations Pituitary and Neuroendocrinology (36 abstracts)

Clinical improvement of hyperglycemia after use of octreotide lar in a patient with acromegaly who presented with nonketotic hyperosmolar state

Umit Cavdar , Nilufer Ozdemir , Bercem Aycicek & Halit Diri

Err

Author affiliations

Gazi Yaşargil Training and Research Hospital, Diyarbakır, Turkey.

A 37-year-old patient with a history of transcranial pituitary surgery because of acromegaly was referred to our clinic with the glucose level 731 mg/dl. she was not using any medication. There was no ketone in the urine and HbA1c was 18.6%. She has 17×16×15 mm of residual macroadenoma on pıtuıtary MRI with level of GH 17.5 ng/ml and IGF-1 422 ng/ml. She was using 140 units of insulin glargin U300 and 100 units of insulin regular per a day before octreotide LAR injection. After the first week of injection her need for insulin decreased day by day. She was using aproximately 70 units of insulin in a day before the second injection of octreotide LAR. It remains controversial whether or not octreotide impairs the glucose levels in patients with acromegaly. We herein present the use of Octreotide LAR as an adjunctive option for the treatment of hyperglycemia in patient with acromegaly who needs to use insulin immediately.